PL EN


Preferences help
enabled [disable] Abstract
Number of results
2014 | 41 | 2 | 155-167
Article title

Wydzielanie serotoniny i melatoniny oraz mioelektryczna i motoryczna czynność żołądka u kobiet po menopauzie

Content
Title variants
EN
Secretion of the serotonin and melatonin and myoelectrical and motor gastric activity in postmenopausal women
Languages of publication
PL
Abstracts
EN
In postmenopausal women various psychosomatic disorders concerning mood and appetite occur. The reason is not only estrogen deficiency, but also other hormones and neurotransmitters. The aim of the study was to estimate serotonin and melatonin levels and myoelectrical activity and gastric motor in postmenopausal women in relation to their nutritional status. The study was conducted in three 30-person groups of women: premenopausal (group I), postmenopausal with a normal body mass (group II), postmenopausal overweight (group III). Compared with group I, in group II there were no significant differences, while in group III serotonin level was lower respectively 156.5±40.2 ng/ml and 83.4±32.5 ng/ml (p<0.01), as well as the percentage of normogastria – 82.9±5.6% and 66.9±8.2 (p<0.05) and gastric emptying half-time 43.6±14.7 min and 27.4±12.2 min (p<0.01). Moreover, a negative correlation between body mass index and serotonin (r = -0.4744) and melatonin (r = -0.7146) levels was observed. The study results indicate the involvement of serotonin and melatonin in the pathogenesis of eating disorders in postmenopausal women.
PL
U kobiet po menopauzie występują różnorodne zaburzenia psychosomatyczne, w tym dotyczące nastroju i łaknienia. Przyczyną tego jest niedobór estrogenów, ale także innych hormonów i neurotransmiterów. Celem badania było określenie stężenia serotoniny i melatoniny oraz czynności mioelektrycznej i motorycznej żołądka u kobiet po menopauzie w odniesieniu do ich stanu odżywienia. Badania przeprowadzono w trzech 30-sto osobowych grupach kobiet: przed menopauzą (grupa I), po menopauzie z prawidłową masą ciała (grupa II), po menopauzie ze współistniejącą nadwagą (grupa III). W porównaniu z grupą I, w grupie II nie stwierdzono istotnych różnic, natomiast w grupie III niższe było stężenie serotoniny, odpowiednio 156,5±40,2 ng/mL i 83,4±32,5 ng/mL (p<0,01), a także niższy był odsetek prawidłowej czynności mioelektrycznej żołądka (normogastrii) – 82,9±5,6% i 66,9±8,2 (p<0,05) oraz krótszy był czas połowicznego opróżniania żołądka (43,6±14,7 min. i 27,4±12,2 min.; p<0,01. Ponadto stwierdzono odwrotną zależność między wskaźnikiem masy ciała a stężeniem serotoniny (r = -0,4744) i melatoniny (r = -0,7146). Wyniki badań wskazują na udział serotoniny i melatoniny w patogenezie zaburzeń odżywiania u kobiet po menopauzie.
Discipline
Publisher

Year
Volume
41
Issue
2
Pages
155-167
Physical description
Contributors
  • Zakład Żywienia Klinicznego i Diagnostyki Gastroenterologicznej, Uniwersytet Medyczny w Łodzi, gastrologia@umed.lodz.pl
  • Klinika Gastroenterologii, Uniwersytet Medyczny w Łodzi
  • Zakład Żywienia Klinicznego i Diagnostyki Gastroenterologicznej, Uniwersytet Medyczny w Łodzi
  • Oddział Gastroenterologii, Szpital Marynarki Wojennej w Gdańsku
  • Zakład Żywienia Klinicznego i Diagnostyki Gastroenterologicznej, Uniwersytet Medyczny w Łodzi
author
  • Klinika Gastroenterologii, Uniwersytet Medyczny w Łodzi
  • Zakład Żywienia Klinicznego i Diagnostyki Gastroenterologicznej, Uniwersytet Medyczny w Łodzi
References
  • Freeman EW, Sammel MD, Lin H, Nelson DB. Associations of hormones and menopausal status with depressed mood in women with no history of depression. Arch Gen Psychiatry. 2006; 63: 375-382.
  • Frey BN, Lord C, Soares CN. Depression during menopausal transition: a review of treatment strategies and pathophysiological correlates. Menopause Int. 2008; 14: 123-128.
  • Freeman EW. Associations of depression with the transition to menopause. Menopause. 2010; 17: 823-827.
  • Everson-Rose SA, Lewis TT, Karavolos K, Dugan SA, Wesley D, Powell LH. Depressive symptoms and increased visceral fat in middle-agedwomen. Psychosom Med. 2009; 71: 410-416.
  • Murabito JM, Massaro JM, Clifford B, Hoffmann U, Fox CS. Depressive symptoms are associated with visceral adiposity in a community-based sample of middle-aged women and men. Obesity. 2013; 21: 1713-1719.
  • Wiltink J, Michal M, Wild PS, Zwiener I, Blettner M, Munzel T i wsp. Associations between depression and different measures of obesity (BMI, WC, WHtR, WHR). BMC Psychiatry. 2013; 13: 223.
  • Asarian L, Geary N. Cyclic estradiol treatment normalizes body weight and restores physiological patterns of spontaneous feeding and sexual receptivity in ovariectomized rats. Horm Behav. 2002; 42: 461-471.
  • Yu Z, Geary N, Corwin RL. Ovarian hormones inhibit fat intake under binge-type conditions in ovariectomized rats. Physiol Behav. 2008; 95: 501-507.
  • Benmansour S, Privratsky AA, Adeniji OS, Frazer A. Signaling mechanisms involved in the acute effects of estradiol on 5-HT clearance. Int J Neuropsychopharmacol. 2014; 17: 765-777.
  • Asarian L, Geary N. Sex differences in the physiology of eating. Am J Physiol RegulIntegr Comp Physiol. 2013; 305: 1215-1267.
  • Geary N. The effect of estrogen on appetite. Medscape Womens Health. 1998; 3: 3.
  • Butera PC, Bradway DM, Cataldo NJ. Modulation of the satiety effect of cholecystokinin by estradiol. Physiol Behav. 1993; 53: 1235-1238.
  • Hutson WR, Roehrkasse RL, Wald A. Influence of gender and menopause on gastric emptying and motility. Gastroenterology. 1989; 96: 11-17.
  • Bond EF, Heitkemper MM, Bailey SL. Estrogen suppresses gastric motility response to thyrotropin-releasing hormone and stress in awake rats. Res Nurs Health. 1998; 21: 221-228.
  • Amure BO, Omole AA. Sex hormones, and acid gastric secretion induced with carbachol, histamine, and gastrin. Gut. 1970; 11: 641-645.
  • Tuo B, Wen G, Wei J, Liu X, Wang X, Zhang Y i wsp. Estrogen regulation of duodenal bicarbonate secretion and sex-specific protection of human duodenum.
  • Gastroenterology. 2011; 141: 854-863.
  • Rossouw JE1, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM i wsp. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007; 297: 1465-1477.
  • Archer DF, Oger E. Estrogen and progestogen effect on venous thromboembolism in menopausal women. Climacteric. 2012; 5: 235-240.
  • Speroff L. Transdermal hormone therapy and the risk of stroke and venous thrombosis. Climacteric. 2010;13: 429-432.
  • Lobo RA. Menopause and stroke and the effects of hormonal therapy. Climacteric. 2007; 10: 27-31.
  • Antoine C, Ameye L, Paesmans M, Rozenberg S. Treatment of climacteric symptoms in breast cancer patients: a retrospective study from a medication databank. Maturitas. 2014;78: 228-232.
  • de Villiers TJ, Pines A, Panay N, Gambacciani M, Archer DF, Baber RJ i wsp. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric. 2013; 16: 316-337.
  • Zhu Y, Hollis JH. Gastric emptying rate, glycemic and appetite response to a liquid meal in lean and overweight males. Int J Food Sci Nutr. 2014; 65: 615-620.
  • Halford JC, Harrold JA, Lawton CL, Blundell JE. Serotonin (5-HT) drugs: effects on appetite expression and use for the treatment of obesity. Curr Drug Targets. 2005; 6(2): 201-213.
  • Bartness TJ, Demas GE, Song CK. Seasonal changes in adiposity: the roles of the photoperiod, melatonin and other hormones, and sympathetic nervous system. Exp Biol Med . 2002; 227: 363-376.
  • Cardinali DP, Pagano ES, Scacchi Bernasconi PA, Reynoso R, Scacchi P. Disrupted chronobiology of sleep and cytoprotection in obesity: possible therapeutic value of melatonin. NeuroEndocrinolLett. 2011; 32: 588-606.
  • Toffol E, Kalleinen N, Haukka J, Vakkuri O, Partonen T, Polo-Kantola P. Melatonin in perimenopausal and postmenopausal women: associations with mood, sleep, climacteric symptoms, and quality of life. Menopause. 2014; 21: 493-500.
  • Blaicher W, Imhof MH, Gruber DM, Schneeberger C, Sator MO, Huber JC. Endocrinological disorders. Focusing on melatonin's interactions. Gynecol Obstet Invest. 1999; 48: 179-182.
  • Blum I1, Vered Y, Lifshitz A, Harel D, Blum M, Nordenberg Y i wsp. The effect of estrogen replacement therapy on plasma serotonin and catecholamines of postmenopausal women. Isr J Med Sci. 1996; 32: 1158-1162.
  • Brewerton TD. 9th annual meeting of the Eating Disorders Research Society. Expert OpinInvestig Drugs. 2004; 13: 73-78.
  • Parkman HP, Hasler WL, Barnett JL, Eaker EY, American Motility Society Clinical GI Motility Testing Task Force. Electrogastrography: a document prepared by the gastric section of the American Motility Society Clinical GI Motility Testing Task Force. Neurogastroenterol Motil. 2003; 15: 89-102.
  • Cucchiara S, Riezzo G, Minella R, Pezzolla F, Giorgio I, Auricchio S. Electrogastrography in non-ulcer dyspepsia. Arch Dis Child. 1992; 67: 613-617.
  • Tabor S, Furgała A, Laskiewicz J, Thor PJ. Electrogastrography and manometry of the stomach in patients with disturbances of basic electrical rhythm. Folia Med. Cracov. 2002; 43: 29-41.
  • Rossi Z, Forlini G, Fenderico P, Cipolla R, Nasoni S. Electrogastrography. Eur Rev Med Pharmacol Sci. 2005; 9: 29-35.
  • Lin X, Chen JZ. Abnormal gastric slow waves in patients with functional dyspepsia assessed by multichannel electrogastrography. Am J Physiol Gastrointest Liver Physiol. 2001; 280: G1370-5.
  • Chen J, McCallum RW. Electrogastrography: measurement, analysis and prospective applications. Med Biol Eng Comput. 1991; 29: 339-350.
  • Riezzo G, Chiloiro M, Russo F, Clemente C, Di Matteo G i wsp. Guerra V Gastric electrical activity and gastrointestinal hormones in dyspeptic patients. Digestion. 2001; 63: 20-29.
  • Yin J, Chen JD. Electrogastrography: methodology, validation and applications. J Neurogastroenterol Motil. 2013; 19: 5-17.
  • Hutson WR, Roehrkasse RL, Wald A. Influence of gender and menopause on gastric emptying and motility. Gastroenterology. 1989; 96: 11-17.
  • Bond EF, Heitkemper MM, Bailey SL. Estrogen suppresses gastric motility response to thyrotropin-releasing hormone and stress in awake rats. Res Nurs Health. 1998; 21: 221-228.
  • Xu X, Chen DD, Yin J, Chen JD. Altered Postprandial Responses in Gastric Myoelectrical Activity and Cardiac Autonomic Functions in Healthy Obeses Subjects. Obes Surg. 2014; 24: 554-560.
  • Walther DJ1, Peter JU, Bashammakh S, Hortnagl H, Voits M, Fink H i wsp. Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science. 2003; 299(5603): 76.
  • Gershon MD. 5-Hydroxytryptamine (serotonin) in the gastrointestinal tract. CurrOpinEndocrinol Diabetes Obes. 2013; 20: 14-21.
  • Hall E, Steiner M. Serotonin and female psychopathology. Womens Health (Lond Engl). 2013; 9: 85-97.
  • Hiroi R, Handa RJ. Estrogen receptor-βregulates human tryptophan hydroxylase- 2 through an estrogen response element in the 5' untranslated region. J Neurochem. 2013; 127: 487-495.
  • Kidd M, Modlin IM, Gustafsson BI, Drozdov I, Hauso O, Pfragner R. Luminal regulation of normal and neoplastic human EC cell serotonin release is mediated by bile salts, amines, tastants, and olfactants. Am J Physiol Gastrointest Liver Physiol. 2008; 295: G260-G272.
  • Garfield AS, Heisler LK. Pharmacological targeting of the serotonergic system for the treatment of obesity. J Physiol. 2009; 587: 49-60.
  • Halford JC, Harrold JA. 5-HT(2C) receptor agonists and the control of appetite. Handb Exp Pharmacol. 2012; 209: 349-356.
  • Brewerton TD. Toward a unified theory of serotonin dysregulation in eating and related disorders. Psychoneuroendocrinology. 1995; 20: 561-590.
  • Asarian L, Geary N. Cyclic estradiol treatment normalizes body weight and restores physiological patterns of spontaneous feeding and sexual receptivity in ovariectomized rats. Horm Behav. 2002; 42: 461-471.
  • Yu Z, Geary N, Corwin RL. Ovarian hormones inhibit fat intake under binge-type conditions in ovariectomized rats. Physiol Behav. 2008; 95(3): 501-507.
  • Johansen B, Bech K. BRL 24924, a 5-hydroxytryptamine type 3 antagonist, and gastric secretion of acid and pepsin in vivo. Digestion. 1991; 48: 121-127.
  • Lepard KJ, Chi J, Mohammed JR, Gidener S, Stephens RL Jr. Gastric antisecretory effect of serotonin: quantitation of release and site of action. Am J Physiol. 1996; 271: 669-677.
  • Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology. 2007; 132: 397-414.
  • van Lelyveld N, Ter Linde J, Schipper ME, Samsom M. Regional differences in expression of TPH-1, SERT, 5-HT(3) and 5-HT(4) receptors in the human stomach and duodenum. Neurogastroenterol Motil. 2007; 19: 342-348.
  • Lim HC, Lee SI, Chen JD, Park H. Electrogastrography associated with symptomatic changes after prokinetic drug treatment for functional dyspepsia. World J Gastroenterol. 2012; 18: 5948-5956.
  • Tan W, Zhou W, Luo HS, Liang CB, Xia H. The inhibitory effect of melatonin on colonic motility disorders induced by water avoidance stress in rats. Eur Rev Med Pharmacol Sci. 2013; 17: 3060-3067.
  • Bubenik GA. Gastrointestinal melatonin: localization, function, and clinical relevance. Dig Dis Sci. 2002; 47: 2336-2348.
  • Reyes-Vazquez C, Naranjo-Rodriguez EB, Garcia-Segoviano JA, Trujillo-Santana JT, Prieto-Gomez B. Apamin blocks the direct relaxant effect of melatonin on rat ileal smooth muscle. J Pineal Res. 1997; 22: 1-8.
  • Kato K, Murai I, Asai S, Takahashi Y, Matsuno Y, Komuro S i wsp. Central nervous system action of melatonin on gastric acid and pepsin secretion in pylorus-ligated rats. Neuroreport. 1998; 9: 2447-2450.
  • Sjoblom M, Flemstrom G. Melatonin in the duodenal lumen is a potent stymulant of mucosal bicarbonate secretion. J Pineal Res. 2003; 34: 288-289.
  • Sartori C, Dessen P, Mathieu C, Monney A, Bloch J, Nicod P i wsp. Melatonin improves glucose homeostasis and endothelial vascular function in high-fat dietfed insulin-resistant mice. Endocrinology. 2009; 150: 5311-5317.
  • Nduhirabandi F, Du Toit EF, Blackhurst D, Marais D, Lochner A. Chronic melatonin consumption prevents obesity-related metabolic abnormalities and protects the heart against myocardial ischemia and reperfusion injury in a prediabetic model of diet-induced obesity. J Pineal Res. 2011; 50: 171-182.
  • Srinivasan V, Ohta Y, Espino J, Pariente JA, Rodriguez AB, Mohamed M i wsp. Metabolic syndrome, its pathophysiology and the role of melatonin. Recent Pat Endocr Metab Immune Drug Discov. 2013; 7: 11-25.
  • Zanuto R, Siqueira-Filho MA, Caperuto LC, Bacurau RF, Hirata E, Peliciari-Garcia RA i wsp. Melatonin improves insulin sensitivity independently of weight loss in old obese rats. J Pineal Res. 2013; 55: 156-165.
  • Wolden-Hanson T, Mitton DR, McCants RL, Yellon SM, Wilkinson CW, Matsumoto AM i wsp. Daily melatonin administration to middle-aged male rats suppresses body weight, intraabdominal adiposity, and plasma leptin and insulin independent of food intake and total body fat. Endocrinology. 2000; 141: 487-497.
  • Hussein MR, Ahmed OG, Hassan AF, Ahmed MA. Intake of melatonin is associated with amelioration of physiological changes, both metabolic and morphological pathologies associated with obesity: an animal model. Int J Exp Pathol. 2007; 88: 19-29.
  • Prunet-Marcassus B, Desbazeille M, Bros A, Louche K, Delagrange P, Renard P i wsp. Melatonin reduces body weight gain in Sprague Dawley rats with dietinduced obesity. Endocrinology. 2003; 144: 5347-5352.
  • Blaicher W, Speck E, Imhof MH, Gruber DM, Schneeberger C, Sator MO i wsp. Melatonin in postmenopausal females. Arch Gynecol Obstet. 2000; 263: 116-118.
  • Rastmanesh R, de Bruin PF. Potential of melatonin for the treatment or prevention of obesity: an urgent need to include weight reduction as a secondary outcome in clinical trials of melatonin in obese patients with sleep disorders. Contemp Clin Trials. 2012; 33: 574-575.
Document Type
paper
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-c18b04a4-1ab9-455f-a161-cb53f9e56c72
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.